Cargando…
Testing previous model predictions against new data on human papillomavirus vaccination program outcomes
BACKGROUND: Vaccination against human papillomavirus (HPV), predominantly targeting young females, has been introduced in many countries. Decisions to implement programs, which have involved substantial investment by governments, have in part been based on findings from cost-effectiveness models. No...
Autores principales: | Smith, Megan A, Canfell, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938033/ https://www.ncbi.nlm.nih.gov/pubmed/24568634 http://dx.doi.org/10.1186/1756-0500-7-109 |
Ejemplares similares
-
Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand
por: Simonella, Leonardo M, et al.
Publicado: (2013) -
Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
por: Simons, Joost J.M., et al.
Publicado: (2022) -
Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data
por: Smith, Megan A., et al.
Publicado: (2016) -
Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
por: Kim, Jane J., et al.
Publicado: (2021) -
Colposcopic outcomes for symptomatic patients with a negative oncogenic human papillomavirus test
por: Mitchell, Georgina, et al.
Publicado: (2021)